Raphael Mechoulam, Ph.D. originated cannabis chemistry when he identified THC in 1964. He and his colleagues have been exploring the therapeutic effects of natural and synthetic cannabinoids ever since.
In 1992, together with William Devane, Ph.D. and Lumir Hanus, Ph.D., the trio labeled the brain’s natural THC as anandamide. These and subsequent discoveries moved toward an appreciation of endocannabinoid functions that produce natural highs as neuroprotective agents.
As noted by David Jay Brown of Mavericks of the Mind, Mechoulam has continued with controlled studies into the therapeutic use of “cannabinoids in the treatment of multiple sclerosis and other spasticity ailments, asthma, rheumatoid arthritis, cancer chemotherapy side-effects, glaucoma, AIDS wasting syndrome, and seizure disorders such as epilepsy.”
What are they up to now?
While New Zealand continues its ban on cannabis use and only reluctantly tolerates the legitimization of pharmaceutical medical cannabis products, the state of Israel could become the first nation in the world to create a federally run cannabis program. It already invests in clinical trials to improve quality strains and research their values.
Where are they going?
Entrepreneurs, medical professionals, researchers, and investors continue to search for the magic bullet of a pure drug.
And, perhaps more important is the interest major world investors are showing. According to Saul Kaye, CEO of iCan, U.S. firms have invested $50 million in Israel medical cannabis research, agro-tech startups, and inhalers, as well as other delivery devices.
Jeffrey Friedland, author and CEO of INTIVA, adds, “the cigarette giant Philip Morris International has announced that it will invest $20 million in a medical cannabis technology company [Syqe Medical].”
History, progress, and investment tells you that Israel leads research in medical cannabis and is very likely to remain the leader. Once you understand how Israel became known as the world’s cannabis research leader, it becomes obvious they are already beyond being the pacesetter. And, until the Ministry of Health make a commitment to support medical cannabis research and/or the New Zealand Government agrees to funding and support, Israel will remain almost impossible to catch up with.